Key facts
- Enrich Biosystems’s last known valuation is $11.9M (May 2022).
- It has raised $8.6M across 3 recorded rounds; the latest was Seed Round ($2.2M) in May 2024.
- Notable investors include MedTech Innovator, National Institutes of Health, Connecticut Innovations, Decent Capital, BioTools Innovator — 15 tracked in total.
- Enrich Biosystems has filed 2 Form Ds with the SEC, most recently May 2024 ($750K sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Enrich Biosystems
Funding rounds
3 roundsAbout Enrich Biosystems
Developer of a novel single-cell isolation technology designed to enhance biomedical research at a true single-cell level. The company's technology uses non-fluidics, dissolvable microwells and visual enrichment strategies to eliminate insurmountable pain points from existing technologies, enabling healthcare professionals to get a streamlined workflow of cell culturing, kinetics profiling and guided capturing based on cell functions.
- Sector
- Healthcare
- HQ
- Branford, CT, United States
- Founded
- 2018
- Employees
- 14
- Website
- enrichbiosystems.com/
- Ownership
- Privately Held (backing)
Enrich Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enrich Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enrich Biosystems in its N-PORT filings yet. We sweep new filings monthly.